[go: up one dir, main page]

WO2002059604A3 - Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques - Google Patents

Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques Download PDF

Info

Publication number
WO2002059604A3
WO2002059604A3 PCT/GB2002/000330 GB0200330W WO02059604A3 WO 2002059604 A3 WO2002059604 A3 WO 2002059604A3 GB 0200330 W GB0200330 W GB 0200330W WO 02059604 A3 WO02059604 A3 WO 02059604A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
mspis
treatment
diagnosis
detectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/000330
Other languages
English (en)
Other versions
WO2002059604A8 (fr
WO2002059604A2 (fr
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Priority to AU2002225219A priority Critical patent/AU2002225219A1/en
Priority to JP2002559670A priority patent/JP2004532386A/ja
Priority to EP02715572A priority patent/EP1354199A2/fr
Publication of WO2002059604A2 publication Critical patent/WO2002059604A2/fr
Publication of WO2002059604A8 publication Critical patent/WO2002059604A8/fr
Publication of WO2002059604A3 publication Critical patent/WO2002059604A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant le criblage, le diagnostic et la prévision de la sclérose en plaques, le suivi de l'efficacité du traitement de la sclérose en plaques, l'identifications des patients les plus susceptibles de répondre à un traitement thérapeutique particulier, et la mise au point de médicaments. Cette invention concerne également les caractéristiques associées à la sclérose en plaques (MSFs) pouvant être détectées par une électrophorèse tridimensionnelle de fluides corporels tels que le liquide céphalo-rachidien. L'invention a également pour objet des isoformes de la protéine associée à la sclérose en plaques (MSPIs) pouvant être détectées dans des fluides corporels tels que le liquide céphalo-rachidien, des préparations combinant des MSPIs isolées, des anticorps immunospécifiques de MSPIs et des kits comprenant les éléments mentionnés ci-dessus.
PCT/GB2002/000330 2001-01-26 2002-01-25 Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques Ceased WO2002059604A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002225219A AU2002225219A1 (en) 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis
JP2002559670A JP2004532386A (ja) 2001-01-26 2002-01-25 多発性硬化症を診断および治療するためのタンパク質、遺伝子、およびこれらの使用
EP02715572A EP1354199A2 (fr) 2001-01-26 2002-01-25 Diagnostic et traitement de la sclerose en plaques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26440401P 2001-01-26 2001-01-26
US60/264,404 2001-01-26
US33164701P 2001-11-20 2001-11-20
US60/331,647 2001-11-20

Publications (3)

Publication Number Publication Date
WO2002059604A2 WO2002059604A2 (fr) 2002-08-01
WO2002059604A8 WO2002059604A8 (fr) 2002-11-21
WO2002059604A3 true WO2002059604A3 (fr) 2003-07-03

Family

ID=26950517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000330 Ceased WO2002059604A2 (fr) 2001-01-26 2002-01-25 Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques

Country Status (4)

Country Link
EP (1) EP1354199A2 (fr)
JP (1) JP2004532386A (fr)
AU (1) AU2002225219A1 (fr)
WO (1) WO2002059604A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968293B2 (en) 2007-08-13 2011-06-28 Baxter International Inc. IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE547101T1 (de) 2000-08-04 2012-03-15 Dmi Biosciences Inc Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
US7015004B2 (en) 2001-11-23 2006-03-21 Syn X Pharma, Inc. Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
NZ539735A (en) 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
EP1627076A4 (fr) * 2003-03-14 2008-07-02 Ppd Biomarker Discovery Scienc Marqueurs biologiques pour le diagnostic de l'arthrite rhumatoide
ES2579635T3 (es) 2003-05-15 2016-08-12 Ampio Pharmaceuticals, Inc. Tratamiento de enfermedades mediadas por los linfocitos T
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2464444T3 (es) 2004-05-12 2014-06-02 The Brigham And Women's Hospital, Inc. Gelsolina para uso en el tratamiento de infecciones
US20050266467A1 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2006005583A2 (fr) * 2004-07-12 2006-01-19 Geneprot Inc. Especes de polypeptides secretes impliques dans la sclerose en plaques
WO2006074787A2 (fr) * 2004-12-27 2006-07-20 Geneprot Inc. Espece de polypeptides utiles pour le traitement de troubles neurologiques
WO2006069739A2 (fr) * 2004-12-27 2006-07-06 Geneprot Inc. Polypeptide utile pour traiter des troubles neurologiques
US20070017809A1 (en) * 2005-07-21 2007-01-25 Power3 Medical Products, Inc. Assay for ALS and ALS-like disorders
US8440622B2 (en) 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
AU2007227613A1 (en) * 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
WO2009020058A1 (fr) * 2007-08-03 2009-02-12 Keio University Système d'administration de médicament vers une lésion de démyélinisation et marqueur biochimique de lésion de démyélinisation
AU2013276992C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
PL2250280T3 (pl) 2008-01-25 2015-06-30 Massachusetts Gen Hospital Terapeutyczne zastosowania gelsoliny w niewydolności nerek
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
WO2010005387A1 (fr) * 2008-07-10 2010-01-14 Astrazeneca Ab Procédé et marqueurs inédits pour le diagnostic de la sclérose en plaques
CA2810844C (fr) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Compositions de diketopiperazine destinees au traitement de syndrome metabolique et de troubles associes
JP6074846B2 (ja) 2010-12-16 2017-02-08 国立研究開発法人産業技術総合研究所 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
EP3721884A1 (fr) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Traitement de maladies articulaires dégénératives avec da-dkp (= diketopiperazine aspartyl-alanyl)
BR112014008036A2 (pt) 2011-10-28 2017-04-11 Ampio Pharmaceuticals Inc tratamento de rinite
ITMI20120865A1 (it) * 2012-05-18 2013-11-19 Antonio Bertolotto Biomarcatori per patologie del sistema nervoso centrale
EP2968315B1 (fr) 2013-03-15 2020-06-03 Ampio Pharmaceuticals, Inc. Compositions pour la mobilisation, l'écotropisme, l'expansion et la différenciation de cellules souches et leurs méthodes d'utilisation
WO2016028790A1 (fr) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Traitement de pathologies articulaires
EP3310375A4 (fr) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies
RU2694614C1 (ru) * 2019-01-22 2019-07-17 Общество с ограниченной ответственностью "ВЕСТТРЭЙД ЛТД" (ООО "ВЕСТТРЭЙД ЛТД") Способ определения активности патологического процесса у больных рассеянным склерозом
WO2020172262A1 (fr) * 2019-02-19 2020-08-27 James Janine Composition à base de chrome et procédés associés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041612A1 (fr) * 1998-02-13 1999-08-19 Oxford Glycosciences (Uk) Ltd. Procedes et compositions de diagnostic du carcinome hepatocellulaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041612A1 (fr) * 1998-02-13 1999-08-19 Oxford Glycosciences (Uk) Ltd. Procedes et compositions de diagnostic du carcinome hepatocellulaire

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOLLENGIER F: "CYSTATIN C ALIAS POST-GAMMA-GLOBULIN A MARKER FOR MULTIPLE SCLEROSIS", JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, vol. 25, no. 9, 1987, pages 589 - 594, XP009003893, ISSN: 0340-076X *
HARRINGTON MICHAEL G ET AL: "Identification of a brain-specific human cerebrospinal fluid glycoprotein, beta-trace protein.", APPLIED AND THEORETICAL ELECTROPHORESIS, vol. 3, no. 5, 1993, pages 229 - 234, XP009003878, ISSN: 0954-6642 *
HIRAOKA ATSUSHI ET AL: "Capillary-zone electrophoretic analyses of the proteins and amino acid components in cerebrospinal fluid of central nervous system diseases.", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 16, no. 10, 1993, pages 949 - 952, XP001121494, ISSN: 0918-6158 *
MARIA ASSUNTA LAURENZI ET AL: "OLIGOCLONAL IGG AND FREE LIGHT CHAINS IN MULTIPLE SCLEROSIS DEMONSTRATED BY THIN-LAYER POLYACRYLAMIDE GEL ISOELECTRIC FOCUSING AND IMMUNOFIXATION", ANNALS OF NEUROLOGY, BOSTON, US, vol. 8, no. 3, September 1980 (1980-09-01), pages 241 - 247, XP001105807, ISSN: 0364-5134 *
MELEGOS D N ET AL: "Prostaglandin D Synthase Concentration in Cerebrospinal Fluid and Serum of Patients with Neurological Disorders", PROSTAGLANDINS, BUTTERWORTH, STONEHAM, MA, US, vol. 54, no. 1, 1 July 1997 (1997-07-01), pages 463 - 474, XP004087867, ISSN: 0090-6980 *
PAGE M J ET AL: "Proteomics: a major new technology for the drug discovery process", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 4, no. 2, February 1999 (1999-02-01), pages 55 - 62, XP002217224, ISSN: 1359-6446 *
ROHLFF C: "PROTEOMICS IN MOLECULAR MEDICINE: APPLICATIONS IN CENTRAL NERVOUS SYSTEMS DISORDERS", ELECTROPHORESIS, WEINHEIM, DE, vol. 21, 2000, pages 1227 - 1234, XP000944098, ISSN: 0173-0835 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968293B2 (en) 2007-08-13 2011-06-28 Baxter International Inc. IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease

Also Published As

Publication number Publication date
AU2002225219A1 (en) 2002-08-06
JP2004532386A (ja) 2004-10-21
WO2002059604A8 (fr) 2002-11-21
EP1354199A2 (fr) 2003-10-22
WO2002059604A2 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
WO2002059604A8 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques
WO2001075454A3 (fr) Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
WO2002054081A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse renale
EP1408333A3 (fr) Diagnostic et traitement de la maladie d'Alzheimer
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO1996003502A3 (fr) Proteines derivees de muc1 destinees au diagnostic, a l'imagerie et a la therapie du cancer humain
WO2001013117A3 (fr) Proteines et genes destines au diagnostic et au traitement du cancer du sein et leur utilisation
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
WO1999047925A3 (fr) Procedes et compositions pour le diagnostic de la polyarthrite rhumatoide
WO2001062784A3 (fr) Proteines
WO2001063294A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de maladies affectives bipolaires (bad) et de depressions unipolaires
WO2001063293A3 (fr) Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
EP1283272A3 (fr) Méthodes et moyens d'évaluation d'une thérapie à base des inhibiteurs de l'enveloppe du VIH
WO2004051269A3 (fr) Proteine de replication
WO2001069261A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
AU2579995A (en) Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
TW200512458A (en) Treatment and diagnostics of cancer
ATE255229T1 (de) Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
IL159479A0 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2002054080A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
WO2002046768A3 (fr) Protéines, gènes, et leur utilisation pour le diagnostic et le traitement de l'asthme chronique
WO2003056341A3 (fr) Methode de diagnostic de cancers du sein, peptides associes et leurs utilisations
WO2001013118A3 (fr) Procedes et compositions permettant le diagnostic de l'hepatome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002715572

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002559670

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002715572

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002715572

Country of ref document: EP